AstraZeneca hails ‘clinically meaningful’ cancer drug trial results

The Financial Times: AstraZeneca has unveiled the results of clinical trials of drugs to treat lung cancer and breast cancer. They showed better results than standard chemotherapy, according to David Fredrickson, the company’s executive vice-president. The conglomerate has worked with Japanese pharmaceutical company Daiichi Sankyo to develop two key “antibody conjugates” that use antibodies to deliver a chemotherapy drug to the tumour with fewer side effects.

▪️ The first drug Enhertu has already changed the approach to breast cancer treatment. Investors have high hopes for the second Dato-DXd.

▪️ More than 600 patients took part in a study of a drug for lung cancer therapy. The new drug helps patients live an average of 4.4 months without tumour growth, compared to 3.7 months with another drug. Another group of patients had a median of 5.6 months compared to 3.7.

▪️ The breast cancer treatment study also showed a “statistically and clinically significant” improvement in the number of times patients survived without tumour growth.

The entire article can be read at the link https://www.ft.com/content/0cb609da-f6b0-4d79-aa84-c972dd60b34e